{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-234177","form_type":"8-K","ticker":null,"cik":"0002032019","company_name":"EQT Infrastructure Co LLC","filed_at":"2026-05-21T18:44:10+00:00","discovered_at":"2026-05-21T18:45:06.589044+00:00","generated_at":"2026-05-21T18:48:44.192602+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"EQT Infrastructure reports Apr 30, 2026 Transactional NAV per share $27.15-$27.55","bullets":["Transactional NAV per share: Class I $27.15, Class A-I $27.22, Class A-S $27.16, Class H $27.55, Class E $27.46, Class Q $27.55, Class T $27.55.","Total Transactional NAV of $575.8M on 21.1M shares outstanding; GAAP NAV $573.0M after $2.8M shareholder servicing fee adjustment.","Portfolio assets at fair value $372.4M (cost $340.1M); cash and equivalents $203.2M; liabilities $12.2M.","Valuation methodology: 68% weighting to discounted cash flow (WACC 12.7%), 32% to market comparables (EV/EBITDA 16.3x).","A 0.25% decrease in WACC would increase asset values by +1.98%; a 0.25% increase would decrease them by -2.03%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-234177","json":"https://secwatch.observer/filing/0001193125-26-234177.json","markdown":"https://secwatch.observer/filing/0001193125-26-234177.md","text":"https://secwatch.observer/filing/0001193125-26-234177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2032019/000119312526234177/0001193125-26-234177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2032019/000119312526234177/ck0002032019-20260420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T18:48:44.192602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-026649","ticker":"VDTA","company_name":"Vertical Data Inc.","filed_at":"2026-06-01T20:47:23+00:00","headline":"Vertical Data launches Vertical Edge, a direct-ownership edge data center platform","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026649","json":"https://secwatch.observer/filing/0001493152-26-026649.json","markdown":"https://secwatch.observer/filing/0001493152-26-026649.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2033264/000149315226026649/0001493152-26-026649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2033264/000149315226026649/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001449794-26-000012","ticker":"EMYB","company_name":"Embassy Bancorp, Inc.","filed_at":"2026-06-01T20:37:17+00:00","headline":"Embassy Bancorp expands stock repurchase program by additional $5M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001449794-26-000012","json":"https://secwatch.observer/filing/0001449794-26-000012.json","markdown":"https://secwatch.observer/filing/0001449794-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/0001449794-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/emyb-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026638","ticker":"XAIR","company_name":"Beyond Air, Inc.","filed_at":"2026-06-01T20:30:41+00:00","headline":"Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026638","json":"https://secwatch.observer/filing/0001493152-26-026638.json","markdown":"https://secwatch.observer/filing/0001493152-26-026638.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315226026638/0001493152-26-026638-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315226026638/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063531","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-06-01T20:30:19+00:00","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063531","json":"https://secwatch.observer/filing/0001213900-26-063531.json","markdown":"https://secwatch.observer/filing/0001213900-26-063531.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063530","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-06-01T20:30:18+00:00","headline":"Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063530","json":"https://secwatch.observer/filing/0001213900-26-063530.json","markdown":"https://secwatch.observer/filing/0001213900-26-063530.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001636282-26-000075","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-01T20:01:39+00:00","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000075","json":"https://secwatch.observer/filing/0001636282-26-000075.json","markdown":"https://secwatch.observer/filing/0001636282-26-000075.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063481","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-01T20:01:27+00:00","headline":"Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063481","json":"https://secwatch.observer/filing/0001213900-26-063481.json","markdown":"https://secwatch.observer/filing/0001213900-26-063481.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm"},"side_by_side_evidence":null},{"accession":"0001606268-26-000032","ticker":"VIASP","company_name":"Via Renewables, Inc.","filed_at":"2026-06-01T19:06:57+00:00","headline":"Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001606268-26-000032","json":"https://secwatch.observer/filing/0001606268-26-000032.json","markdown":"https://secwatch.observer/filing/0001606268-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/0001606268-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/spke-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}